Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin treatment optimization in neonatal and pediatric inpatients
RBR-7pjwxp6Recruiting
- Sponsor
- Faculdade de Ciências Farmacêuticas da Universidade de São Paulo
- Start
- May 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vancomycin in bacterial disease and sepsis, sponsored by Faculdade de Ciências Farmacêuticas da Universidade de São Paulo. Primary endpoints: Evaluation of a new vancomycin pharmacokinetic-pharmacodynamic effectiveness prediction index and Development of a population pharmacokinetic model for clinical application. Started May 2025; status: recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial diseasesepsis
Beyond the preview
Go deeper on RBR-7pjwxp6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7pjwxp6.